'%20fill='%23101C45'%3e%3cg%20id='编组-5'%20transform='translate(360.000000,%2034.000000)'%3e%3cg%20id='电话'%20transform='translate(1160.000000,%2017.000000)'%3e%3cpath%20d='M13.1609753,6.15257283%20C14.5557846,6.17005251%2015.7944079,7.12542605%2016.1727856,8.4740923%20C16.2746461,8.83952678%2016.3102293,9.21561293%2016.2795354,9.59224533%20C16.2458535,10.0016521%2016.5487186,10.3602586%2016.9553456,10.3938523%20C16.9759893,10.3957642%2016.9963614,10.3963104%2017.0167335,10.3963104%20C17.3975559,10.3963104%2017.7207931,10.1024334%2017.7525735,9.71405682%20C17.7976638,9.16071582%2017.744968,8.60874043%2017.5955726,8.07178663%20C17.0406368,6.09248645%2015.2248042,4.69192741%2013.1797176,4.66625413%20L13.169939,4.66625413%20C12.7660283,4.66625413%2012.436272,4.99290558%2012.4313827,5.39985428%20C12.4262217,5.81062667%2012.7527185,6.14765667%2013.1609753,6.15257283%20Z%20M22.2504602,6.55023546%20C21.1835058,2.74267041%2017.6906424,0.0488884688%2013.7566553,0%20L13.7471483,0%20C13.3432376,0%2013.0134813,0.326651445%2013.0085317,0.734146392%20C13.0034311,1.14464566%2013.3304711,1.48112942%2013.7387278,1.4863187%20C17.0221661,1.52728669%2019.9375485,3.77561002%2020.8284881,6.95445297%20C21.0699653,7.81232269%2021.1568862,8.69777753%2021.086263,9.58623669%20C21.0542109,9.99564347%2021.3576192,10.3537037%2021.7642462,10.386205%20C21.7843467,10.3875706%2021.8041755,10.3883899%2021.8237328,10.3883899%20C22.2050983,10.3883899%2022.5288788,10.0934204%2022.5598444,9.70449762%20C22.6443207,8.63878362%2022.5400156,7.57743955%2022.2504602,6.55023546%20Z%20M17.9535782,15.6915598%20C17.1845996,15.1709932%2015.7169939,14.3295106%2014.5049902,14.5433636%20C14.115257,14.6073559%2013.7557618,14.7940196%2013.4782367,15.0764937%20L12.8043278,15.7756807%20C11.5491352,15.7314353%2010.1214589,14.8885872%208.97002814,13.5096046%20C7.8185974,12.1308951%207.2405732,10.5711072%207.41387181,9.32076411%20L8.21517416,8.77343175%20C9.23703838,8.07479095%209.34405978,6.56935386%208.52075557,4.52942104%20C7.85689694,2.88878958%206.0535592,-0.117441573%203.96908658,0.252089702%20C3.76696221,0.28782123%203.57170746,0.355383616%203.39051912,0.452286617%20L2.00032744,1.19298789%20C0.808424145,1.82990358%200.0473227245,3.06003578%200.00549202541,4.41662251%20C-0.113481002,8.38724016%201.70533952,12.9213042%204.99230894,16.8635174%20C8.27927835,20.8057306%2012.4156283,23.3905377%2016.3210944,23.9608121%20C17.6575038,24.1555466%2018.9952713,23.6153154%2019.8261811,22.5452315%20L20.7923616,21.298439%20C21.1335262,20.8573503%2021.5776379,19.8929638%2020.6905011,18.4104687%20C19.9693122,17.3283294%2019.03844,16.403584%2017.9535782,15.6915598%20Z'%20id='形状'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
Global Innovation Local Roots
全球科创标杆 亚太深耕典范
福泰香港作为 Vertex布局亚太的核心战略载体，立足香港国际金融与医疗创新双优势，集全球技术赋能、雄厚资本支撑、顶尖团队加持、顶级生态协同于一体，以资本驱动、技术转化、区域落地为核心发展逻辑，携手全球顶尖产业、科研与资本伙伴，打造链接全球生物医药创新与亚太市场需求的核心枢纽，是亚太生物医药领域兼具全球视野与本土深耕能力的标杆型平台企业。
- 基因编辑
- 干细胞疗法
- 小分子药物
- 囊性纤维化
- 罕见病
福泰香港携手超30家全球及亚太顶尖合作方，12家核心战略伙伴覆盖研、投、商全产业链
Development History
发展历程
福泰制药融投科技 (香港) 有限公司成立于 2025 年，是 1989 年创立于美国波士顿的全球生物医药创新领军者 Vertex Pharmaceuticals（NASDAQ:VRTX）的全资子公司，总部落子中国香港，被母公司定调为亚太地区资本与战略双枢纽。背靠Vertex的全球布局与硬核实力——其在伦敦、旧金山、东京等核心城市设研发与商业中心，在囊性纤维化、基因编辑疗法等领域斩获多项突破性进展，还屡登《财富》“最佳雇主”、《时代》周刊全球最具影响力公司榜单，福泰香港自成立之初便获得母公司全维度的技术、资源与资金支撑，成为Vertex深耕亚太市场的核心战略载体。
1989
公司成立
2025
子公司成立
Mission anchors
dividends foundation
使命锚向 红利筑基
核心使命
锚定发展核心主线
福泰香港以搭建亚太医药投融资平台、推动全球创新药区域商业化、构建区域性医药创新生态圈为三大核心使命，锚定 “资本 + 技术 + 生态” 发展主线，推动业务围绕投融资、药物转化、产业资源整合全方位布局，贴合亚太生物医药产业升级需求，构筑差异化核心竞争力。资本 技术 生态3区位红利
筑牢全球区域链接枢纽
依托香港国际金融中心与亚太医疗创新枢纽双重优势，福泰香港可高效链接全球资本与亚太本土市场，同时辐射粤港澳大湾区及东南亚核心区域，为三大核心使命落地提供地理与资源链接的核心支撑。政策红利
扫清业务落地关键障碍
香港拥有生物医药IPO高活跃度、创新药审查加速等产业利好，叠加区域产业资本支持政策，精准匹配公司投融资平台搭建、创新药区域商业化的业务需求，为核心使命落地扫清关键政策与市场障碍。政策利好 资本支持 市场优势IPO
company strength
公司实力
坐拥全球顶尖技术壁垒、雄厚稳健资本实力、潜力巨大市场布局、得天独厚政策区位红利与完善产业生态布局；以母公司四大核心技术平台为根基，联动亚太本土资源实现技术本土化转化；背靠母公司超百亿美金营收，依托香港国际金融中心开展多元资本运作，直面亚太超1亿罕见病患者临床需求，打造多业务协同增长闭环。
Team Strength
团队实力
- 01
%3c/title%3e%3cg%20id='页面-1'%20stroke='none'%20stroke-width='1'%20fill='none'%20fill-rule='evenodd'%3e%3cg%20id='关于福泰'%20transform='translate(-1068.000000,%20-3614.000000)'%20fill='%238E9AC0'%20fill-rule='nonzero'%3e%3cg%20id='编组-42'%20transform='translate(360.000000,%203434.000000)'%3e%3cg%20id='编组-40'%20transform='translate(408.000000,%20136.000000)'%3e%3cg%20id='编组-39'%20transform='translate(280.000000,%2024.000000)'%3e%3cg%20id='战略-(1)'%20transform='translate(20.000000,%2020.000000)'%3e%3cpath%20d='M20,3.696%20C25.7162495,3.696%2030.9982819,6.74558263%2033.8564067,11.696%20C36.7145315,16.6464172%2036.7145315,22.7455828%2033.8564067,27.696%20C30.9982819,32.6464174%2025.7162495,35.696%2020,35.696%20C11.163444,35.696%204,28.532556%204,19.696%20C4,10.859444%2011.163444,3.696%2020,3.696%20L20,3.696%20Z%20M20,6.36266667%20C12.6362033,6.36266667%206.66666667,12.3322033%206.66666667,19.696%20C6.66666667,27.0597967%2012.6362033,33.0293333%2020,33.0293333%20C27.3637967,33.0293333%2033.3333333,27.0597967%2033.3333333,19.696%20C33.3333333,12.3322033%2027.3637967,6.36266667%2020,6.36266667%20L20,6.36266667%20Z'%20id='形状'%3e%3c/path%3e%3cpath%20d='M17,20%20C17,21.6568542%2018.3431458,23%2020,23%20C21.6568542,23%2023,21.6568542%2023,20%20C23,18.3431458%2021.6568542,17%2020,17%20C18.3431458,17%2017,18.3431458%2017,20%20L17,20%20Z'%20id='路径'%3e%3c/path%3e%3cpath%20d='M20,0%20L20,0%20C20.8888889,0%2021.3333333,0.444444444%2021.3333333,1.33333333%20L21.3333333,9.33333333%20C21.3333333,10.2222222%2020.8888889,10.6666667%2020,10.6666667%20L20,10.6666667%20C19.1111111,10.6666667%2018.6666667,10.2222222%2018.6666667,9.33333333%20L18.6666667,1.33333333%20C18.6666667,0.444444444%2019.1111111,0%2020,0%20Z'%20id='路径'%3e%3c/path%3e%3cpath%20d='M20,29.3333333%20L20,29.3333333%20C20.8888889,29.3333333%2021.3333333,29.7777778%2021.3333333,30.6666667%20L21.3333333,38.6666667%20C21.3333333,39.5555556%2020.8888889,40%2020,40%20L20,40%20C19.1111111,40%2018.6666667,39.5555556%2018.6666667,38.6666667%20L18.6666667,30.6666667%20C18.6666667,29.7777778%2019.1111111,29.3333333%2020,29.3333333%20Z'%20id='路径'%3e%3c/path%3e%3cpath%20d='M40,20%20L40,20%20C40,20.8888889%2039.5555556,21.3333333%2038.6666667,21.3333333%20L30.6666667,21.3333333%20C29.7777778,21.3333333%2029.3333333,20.8888889%2029.3333333,20%20L29.3333333,20%20C29.3333333,19.1111111%2029.7777778,18.6666667%2030.6666667,18.6666667%20L38.6666667,18.6666667%20C39.5555556,18.6666667%2040,19.1111111%2040,20%20L40,20%20Z'%20id='路径'%3e%3c/path%3e%3cpath%20d='M10.6666667,20%20L10.6666667,20%20C10.6666667,20.8888889%2010.2222222,21.3333333%209.33333333,21.3333333%20L1.33333333,21.3333333%20C0.444444444,21.3333333%200,20.8888889%200,20%20L0,20%20C0,19.1111111%200.444444444,18.6666667%201.33333333,18.6666667%20L9.33333333,18.6666667%20C10.2222222,18.6666667%2010.6666667,19.1111111%2010.6666667,20%20L10.6666667,20%20Z'%20id='路径'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
团队定位
打造兼具全球战略视野与本土实操能力的顶尖团队体系
- 02
治理结构
董事会由 Vertex 全球高层与香港本地生物医药专家联合组成
- 03
'%20fill='%238E9AC0'%20fill-rule='nonzero'%3e%3cg%20id='编组-42'%20transform='translate(360.000000,%203434.000000)'%3e%3cg%20id='编组-40备份'%20transform='translate(408.000000,%20400.000000)'%3e%3cg%20id='编组-39'%20transform='translate(280.000000,%2024.000000)'%3e%3cg%20id='企业人才库_画'%20transform='translate(24.000000,%2024.000000)'%3e%3cpath%20d='M15.6684574,13.40109%20C18.3004504,11.6153069%2019.4760887,8.29707286%2018.5667854,5.22057177%20C17.6574821,2.14407068%2014.8759643,0.0290351041%2011.709446,0.00614164572%20C8.54292772,-0.0163826926%205.73220058,2.05854772%204.78009613,5.1216996%20C3.82799167,8.18485148%204.95725016,11.5196152%207.56408289,13.3429689%20C3.11359965,14.5504974%200.0135910394,18.633911%200,23.3065795%20L0,28.2883849%20C0.0180113969,30.3532691%201.68067341,32.0136466%203.71655155,31.9999154%20L19.352264,31.9999154%20C21.3849065,31.9952636%2023.0315686,30.3251128%2023.0360706,28.2634758%20L23.0360706,23.2816705%20C23.0079591,18.6968943%2020.0103277,14.6768218%2015.6684574,13.40109%20L15.6684574,13.40109%20Z%20M11.6572013,2.49092909%20C13.5849586,2.48757671%2015.3247389,3.66280886%2016.064756,5.46826622%20C16.804773,7.27372357%2016.3991752,9.35356436%2015.0372155,10.7373292%20C13.6752558,12.1210941%2011.625366,12.5360537%209.84403033,11.7885867%20C8.06269462,11.0411196%206.9009977,9.27854602%206.9009977,7.32328745%20C6.90548697,4.65958042%209.03096778,2.50007034%2011.6572013,2.49092909%20Z%20M20.5474546,28.2302638%20C20.5474546,28.9181076%2019.9976891,29.4757151%2019.3195191,29.4757151%20L3.71655155,29.4757151%20C3.03838148,29.4757151%202.48861602,28.9181076%202.48861602,28.2302638%20L2.48861602,23.2484585%20C2.49312801,18.9169397%205.95400877,15.4066914%2010.2246099,15.4021151%20L12.8442057,15.4021151%20C17.1148068,15.4066914%2020.5756876,18.9169397%2020.5801996,23.2484585%20L20.5474546,28.2302638%20Z'%20id='形状'%3e%3c/path%3e%3cpath%20d='M25.4018931,12.8281823%20C27.6775881,10.8277633%2028.486356,7.60270598%2027.4295732,4.74256874%20C26.3727903,1.8824315%2023.6734761,-0.00919336519%2020.6620619,0%20C20.2233628,0%2019.8179881,0.23741528%2019.5986385,0.622759267%20C19.379289,1.00810325%2019.379289,1.48286663%2019.5986385,1.86821061%20C19.8179881,2.2535546%2020.2233628,2.49093628%2020.6620619,2.49093627%20C22.4098407,2.41740758%2024.0567924,3.32123759%2024.9522824,4.84536486%20C25.8477725,6.36949212%2025.8477725,8.26877974%2024.9522824,9.792907%20C24.0567924,11.3170343%2022.4098407,12.2208643%2020.6620619,12.1473356%20C19.9838918,12.1473356%2019.4341263,12.7049431%2019.4341263,13.3927869%20C19.4341263,14.0806307%2019.9838918,14.6382383%2020.6620619,14.6382383%20C20.9356946,14.6389946%2021.2091051,14.622356%2021.4806856,14.5884202%20C21.5867215,14.6217351%2021.6971288,14.6385324%2021.8081351,14.6382383%20C26.0787362,14.6428146%2029.5396169,18.1530629%2029.5441289,22.4845817%20L29.5441289,27.466387%20C29.5441289,28.1542308%2028.9943635,28.7118383%2028.3161934,28.7118383%20C27.6381045,28.7119547%2027.0884657,29.2695282%2027.0884657,29.9572896%20C27.0884657,30.6450511%2027.6381045,31.202741%2028.3161934,31.202741%20C30.3488359,31.1981747%2031.995498,29.528024%2032,27.466387%20L32,22.4845817%20C31.990731,18.1884908%2029.3646916,14.3452543%2025.4018931,12.8281823%20L25.4018931,12.8281823%20Z'%20id='路径'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
人才组织
汇聚多领域资深人才，设四大核心职能部门，构建全球化人才梯队
- 04
'%20fill='%238E9AC0'%20fill-rule='nonzero'%3e%3cg%20id='编组-42'%20transform='translate(360.000000,%203434.000000)'%3e%3cg%20id='编组-40备份-3'%20transform='translate(816.000000,%20400.000000)'%3e%3cg%20id='编组-39'%20transform='translate(280.000000,%2024.000000)'%3e%3cpath%20d='M48.0642857,21.6577415%20C48.1435045,21.8778029%2048.1918275,22.1079129%2048.2078572,22.3414159%20L48.2142857,22.5168277%20L48.2142857,34.2277174%20L54.2421429,39.1989145%20L54.295,39.2348595%20C54.916681,39.6749146%2055.3057019,40.3757081%2055.3521429,41.1392271%20L55.3571428,41.2923529%20L55.3571428,57.1282938%20L58.9285714,57.1290127%20C59.5203051,57.1290127%2060,57.6118068%2060,58.2073635%20C60,58.8029202%2059.5203051,59.2857143%2058.9285714,59.2857143%20L21.0714286,59.2857143%20C20.4796949,59.2857143%2020,58.8029202%2020,58.2073635%20C20,57.6118068%2020.4796949,57.1290127%2021.0714286,57.1290127%20L24.6428572,57.1290127%20L24.6428572,27.2220317%20C24.6430281,26.2165895%2025.2379016,25.3077724%2026.1557143,24.9107665%20L26.2885715,24.8582867%20L26.3928572,24.8259362%20L44.9292857,20.129359%20L44.99,20.1085109%20C46.2609382,19.7212104%2047.6109655,20.4015323%2048.0642857,21.6577415%20Z%20M45.6542857,22.1624097%20L45.5921428,22.1796633%20L45.4878571,22.211295%20L26.9928572,26.8985264%20L26.9635715,26.9129044%20C26.8730731,26.9657523%2026.8101518,27.0558827%2026.7914286,27.1594873%20L26.7857143,27.2234695%20L26.7857143,57.1282938%20L46.0714286,57.1282938%20L46.0714286,22.5168277%20C46.0714286,22.4109236%2046.0250701,22.310399%2045.944665,22.2420843%20C45.86426,22.1737696%2045.7580144,22.1446178%2045.6542857,22.1624097%20L45.6542857,22.1624097%20Z%20M48.2142857,37.0148947%20L48.2142857,57.1282938%20L53.2142857,57.1282938%20L53.2142857,41.2923529%20C53.2141319,41.189473%2053.1701855,41.0915905%2053.0935714,41.0234841%20L52.9264286,40.9019899%20L48.2142857,37.0156136%20L48.2142857,37.0148947%20Z%20M36.4285714,43.0062118%20C40.1010672,43.0062118%2043.1070524,45.946934%2043.2114286,49.6416637%20L43.2142857,49.8357668%20L41.0714286,49.8357668%20C41.0733994,47.2862605%2039.0445334,45.2057303%2036.5117994,45.1600286%20C33.9790653,45.1143269%2031.8774039,47.1203241%2031.7885714,49.668263%20L31.7857143,49.8357668%20L29.6428571,49.8357668%20C29.6428571,48.0244562%2030.3577786,46.2873321%2031.6303468,45.0065421%20C32.9029151,43.7257521%2034.6288881,43.0062118%2036.4285714,43.0062118%20L36.4285714,43.0062118%20Z%20M36.4285714,34.3794054%20C37.8322114,34.3792596%2039.1292902,35.1328468%2039.831152,36.356264%20C40.5330138,37.5796812%2040.5330138,39.0870354%2039.831152,40.3104526%20C39.1292902,41.5338698%2037.8322114,42.287457%2036.4285714,42.2873112%20C34.2590397,42.2870858%2032.5004055,40.5169068%2032.5004055,38.3333583%20C32.5004055,36.1498098%2034.2590397,34.3796308%2036.4285714,34.3794054%20L36.4285714,34.3794054%20Z%20M36.4285714,36.536107%20C35.7905321,36.5360087%2035.2009176,36.8785413%2034.8818697,37.4346532%20C34.5628218,37.9907651%2034.5628218,38.6759515%2034.8818697,39.2320634%20C35.2009176,39.7881753%2035.7905321,40.1307079%2036.4285714,40.1306096%20C37.4146874,40.1304577%2038.2140124,39.3258454%2038.2140124,38.3333583%20C38.2140124,37.3408712%2037.4146874,36.5362589%2036.4285714,36.536107%20L36.4285714,36.536107%20Z'%20id='形状'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
核心文化
以 “科学至上、资本驱动、区域深耕” 为核心文化理念
Industrial EcosystemCooperation
产业生态合作
Industrial EcosystemCooperation
产业生态合作
核心战略合作伙伴
联动全球生物医药创新龙头企业，共享技术成果、产业经验与全球布局，协同推进前沿创新疗法亚太落地，打造全球创新与区域转化的战略合作典范。
01资本与产业生态合作方
携手亚太资本平台与港交所，打造生物医药产业投资基金，以资本活水浇灌产业创新，实现资本与产业深度融合、双向赋能。
02科研与落地合作机构
携手全球顶尖科研院所、香港及亚太本土高校、核心医疗企业，共建研产平台，搭建商业化渠道，推动前沿技术本土化研发与创新药快速市场准入。
03
Corporate Vision & Values
企业愿景与价值观
Vertex
愿景
致力于成为亚洲领先的生物医药投资与商业化平台，成长为 Vertex 全球战略版图中最具价值的成长引擎，以科创与资本双轮驱动亚太生物医药产业升级，让全球前沿创新疗法惠及亚太广大患者，实现产业与社会价值深度融合。
Vertex
价值观
承袭母公司 “无畏、多元、协作、以患者为中心” 的核心价值观，秉持科学至上、资本驱动、区域深耕的发展理念，以创新为基、以合作为桥、以责任立身，携手各界共筑亚太生物医药产业新生态。
Latest News
最新资讯
'%20fill='%23101C45'%20fill-rule='nonzero'%3e%3cg%20id='编组-13'%20transform='translate(360.000000,%205503.000000)'%3e%3cg%20id='编组-5备份'%20transform='translate(1036.000000,%2052.000000)'%3e%3cg%20id='编组'%20transform='translate(128.000000,%2024.000000)'%3e%3cpath%20d='M8.91579345,-0.485997675%20L8.99836297,-0.426028799%20L14.3924364,4.28240003%20L14.4260288,4.31774416%20C14.4498702,4.34506238%2014.4706162,4.37402405%2014.488296,4.40420066%20L14.517769,4.46193844%20L14.5401404,4.52195808%20L14.5604274,4.61417974%20L14.5654643,4.68972791%20L14.5604223,4.76492505%20L14.5401386,4.85714723%20L14.5178035,4.91712837%20L14.473763,4.99836961%20L14.4260288,5.06135806%20L14.371807,5.11557991%20L8.99836297,9.80513102%20C8.76307376,10.0104743%208.40587053,9.98619839%208.20052722,9.75090918%20C8.01799983,9.54176321%208.01690001,9.23629012%208.18416016,9.02677009%20L8.25474906,8.95307343%20L12.491,5.255%20L2.22044605e-16,5.25500752%20C-0.31229295,5.25500752%20-0.565456406,5.00184406%20-0.565456406,4.68955111%20C-0.565456406,4.40848746%20-0.360394006,4.17531869%20-0.0917199662,4.13149558%20L2.22044605e-16,4.12409471%20L12.492,4.124%20L8.25474906,0.426028799%20C8.01945986,0.22068549%207.99518391,-0.136517743%208.20052722,-0.371806952%20C8.36023868,-0.55480967%208.61181602,-0.61016239%208.82644654,-0.529110852%20L8.91579345,-0.485997675%20Z'%20id='形状结合'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
- 公司新闻
Vertex提供产品线和业务最新进展
为公司在2026年的持续增长和诸多重要里程碑奠定了基础，”他说道。雷什玛·凯瓦拉玛尼医学博士、首席执行官兼总裁“在此势头的基础上，我们专注于扩大我们在多个疾病领域的商业覆盖范围；推进新兴的肾脏产品线，包括近期推出 povetacicept；以及推进我们的中后期临床研发管线。凭借不断扩充的变革性药物组合，我们已做好充分准备为更多患者提供服务，并在此过程中为股东带来持续增长和长期价值。”
012026.03'%20fill='%23FFFFFF'%20fill-rule='nonzero'%3e%3cg%20id='编组-13'%20transform='translate(360.000000,%205503.000000)'%3e%3cg%20id='蒙版-4'%20transform='translate(0.000000,%20136.000000)'%3e%3cg%20id='编组'%20transform='translate(337.434544,%20415.434536)'%3e%3cpath%20d='M9.48124985,0.0794667772%20L9.56381937,0.139435653%20L14.9372634,4.82898677%20L14.97,4.863%20L14.9914852,4.88320861%20C14.9939894,4.88607799%2014.9964594,4.8889655%2014.9988954,4.89187065%20L14.9372634,4.82898677%20C14.972856,4.86004941%2015.0036199,4.89458708%2015.0294908,4.9316521%20C15.0397695,4.94650608%2015.049374,4.96177244%2015.058173,4.97734866%20C15.066147,4.99139748%2015.0735617,5.00601008%2015.0803075,5.02086649%20C15.0865988,5.03465012%2015.0923454,5.04877453%2015.0974936,5.06305419%20C15.104532,5.08280818%2015.1103966,5.10246826%2015.1151771,5.12235216%20C15.1178558,5.13320008%2015.1201218,5.14402945%2015.1220664,5.15490022%20C15.1256361,5.1751113%2015.1281965,5.19585419%2015.1296115,5.21667493%20C15.1304957,5.22924718%2015.1309301,5.24222271%2015.1309207,5.25519236%20C15.1309073,5.26847896%2015.130473,5.28111874%2015.129616,5.29374076%20C15.1281965,5.31417694%2015.1256361,5.33491983%2015.1219372,5.35548225%20C15.1201218,5.36600168%2015.1178558,5.37683105%2015.1152675,5.38760405%20C15.1103966,5.40756287%2015.104532,5.42722295%2015.0975901,5.4465634%20C15.0923454,5.4612566%2015.0865988,5.47538101%2015.0802514,5.48931271%20C15.0735617,5.50402105%2015.066147,5.51863365%2015.0580666,5.53295525%20C15.049374,5.54825869%2015.0397695,5.56352504%2015.0293556,5.57842377%20C15.0036199,5.61544405%2014.972856,5.64998172%2014.9372634,5.68104436%20L14.9988954,5.61816048%20C14.9964594,5.62106562%2014.9939894,5.62395314%2014.9914852,5.62682252%20L14.97,5.646%20L14.9372634,5.68104436%20L9.56381937,10.3705955%20L9.48124985,10.4305644%20C9.25102648,10.567939%208.94851101,10.5255196%208.76598362,10.3163736%20C8.56064031,10.0810844%208.58491626,9.72388119%208.82020547,9.51853788%20L8.82020547,9.51853788%20L13.057,5.82%20L0.565456406,5.82047197%20C0.253163456,5.82047197%200,5.56730851%200,5.25501556%20C0,4.97395191%200.2050624,4.74078314%200.47373644,4.69696003%20L0.565456406,4.68955916%20L13.057,4.689%20L8.82020547,0.991493251%20C8.58491626,0.786149941%208.56064031,0.428946709%208.76598362,0.1936575%20C8.94851101,-0.0154884635%209.25102648,-0.0579078997%209.48124985,0.0794667772%20Z'%20id='形状结合'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
- 公司新闻
Vertex公司在美国肾脏病学会肾脏周上公布了RUBY-3研究的最新1/2期数据，这些数据继续表明Povetacicept在治疗成人IgA肾病和原发性膜性肾病方面具有同类最佳的潜力。
- 48 周数据显示，IgA 肾病患者的蛋白尿较基线下降 64%，原发性膜性肾病患者的蛋白尿较基线下降 82%，两种疾病的估计肾小球滤过率均趋于稳定 - -正按计划启动生物制品许可申请的滚动提交，以期获得可能的加速批准。美国食品药品监督管理局今年；IgA肾病3期RAINIER试验已完成全部受试者招募—— - Povetacicept 在原发性膜性肾病中获得了快速通道资格认定美国食品药品监督管理局已启动二/三期关键性试验 -
292026.01 - 公司新闻
Vertex宣布肾脏产品组合取得重大进展
美国食品药品监督管理局povetacicept 获得 IgA 肾病突破性疗法认定；有望申请加速审批。我们2026年上半年，如果36周中期分析数据为阳性 - - AMPLITUDE 全球 2/3 期试验的中期分析队列已完成入组，该试验旨在评估 inaxaplin 在 APOL1 介导的肾脏疾病中的疗效；有可能申请加速批准。我们如果48周中期分析数据为阳性—— -针对常染色体显性多囊肾病患者的VX-407二期概念验证研究已启动
142026.01